{
  "id": "626aed2fe764a53204000043",
  "type": "factoid",
  "question": "For which indication has inotersen been approved?",
  "ideal_answer": "Inoteresen has been approved for patients in stage 1 and stage 2 hereditary transthyretin amyloidosis polyneuropathy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32865784"
  ],
  "snippets": [
    {
      "text": "Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32865784",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A new drug named inotersen (brand name Tagsedi), also known as IONIS-TTRRX, has been approved by the United States Food and Drug Agency, Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32865784",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "stage 1 and stage 2 hereditary transthyretin amyloidosis polyneuropathy"
}